日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Optimization and Validation of a Harmonized Protocol for Generating Therapeutic-Grade Dendritic Cells in a Randomized Phase II Clinical Trial, Using Two Varied Antigenic Sources

在随机 II 期临床试验中使用两种不同抗原来源生成治疗级树突状细胞的协调方案的优化和验证

Abirami Seetharaman, Vasanth Christopher, Hemavathi Dhandapani, Hascitha Jayakumar, Manikandan Dhanushkodi, Narmadha Bhaskaran, Swaminathan Rajaraman, Rama Ranganathan, Shirley Sunder Singh, Varalakshmi Vijayakumar, Arivazhagan Rajamanickam, Anil Suri, Nirmala Jagadish, Thangarajan Rajkumar, Priya R

Combination of IDO1high and CCL19low expression in the tumor tissue reduces survival in HPV positive cervical cancer

肿瘤组织中 IDO1high 和 CCL19low 表达的组合降低了 HPV 阳性宫颈癌的生存率

Hascitha Jayakumar, Abirami Seetharaman, Shirley Sunder Singh, Hemavathi Dhandapani, Jayavelu Subramani, Selvaluxmy Ganeshrajah, Rajkumar Thangarajan, Priya Ramanathan

Dendritic cells matured with recombinant human sperm associated antigen 9 (rhSPAG9) induce CD4+, CD8+ T cells and activate NK cells: a potential candidate molecule for immunotherapy in cervical cancer

用重组人精子相关抗原 9 (rhSPAG9) 成熟的树突状细胞诱导 CD4+、CD8+ T 细胞并激活 NK 细胞:宫颈癌免疫治疗的潜在候选分子

Hemavathi Dhandapani, Hascitha Jayakumar, Abirami Seetharaman, Shirley Sunder Singh, Selvaluxmy Ganeshrajah, Nirmala Jagadish, Anil Suri, Rajkumar Thangarajan, Priya Ramanathan

Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro

自体宫颈肿瘤裂解物脉冲刺激树突状细胞后,再用顺铂治疗,可在体外消除FOXP3+细胞。

Hemavathi Dhandapani ,Abirami Seetharaman ,Hascitha Jayakumar ,Selvaluxmy Ganeshrajah ,Shirley Sunder Singh ,Rajkumar Thangarajan ,Priya Ramanathan